Roche says divarasib cut risk of death 44% in lung cancer trial

Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced ​the risk of death by 44% compared ‌with existing treatments in a phase III study.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.reuters.com)